Yes,
being a small bio tech company, open to be taken over by nig pharmas (attractive premium) is always a popular option.
i dare to say pxs's share price will be much much higher if the management make this approach.
investors will be very cautious to buy into a company only seeking “parters”.did the BI deal move the share prices at all in the past 2 years?